Developing Update · Europe — Politics: live coverage

Abivax shares surge following positive clinical trial data

French biotechnology firm Abivax has reported that new clinical trial results support the safety and efficacy of its experimental treatment for ulcerative colitis.

By Europa Express 30 Jun 2026 · 11:30 CET Updated 30 Jun 2026 · 11:30 CET

Text:

⚡ EXECUTIVE DISPATCH BRIEF Developing · Politics

Core Briefing: Abivax shares surge following positive clinical trial data
Strategic Context: French biotechnology firm Abivax has reported that new clinical trial results support the safety and efficacy of its experimental treatment for ulcerative colitis.
Fact Checking & Evidence: Documented status is developing across primary accredited European reporting wires and official filings.
Editorial Integrity: Independent coverage adhering to the Europa Express European Press Standards and source verification framework.

AI disclosure: Summarised from a single named source by an AI model with editorial rules; links to the original report.

Shares in French biotech company Abivax rose by 36% on 30 June following the release of new clinical trial data. According to Euronews, the findings provide support for the safety and effectiveness of the firm's experimental drug, obefazimod, which is being developed as a treatment for ulcerative colitis.

Source: Euronews. Read the original report ↗

📊 EUROPEAN POLICY & IMPACT PULSE

How impactful is this development for European policy and regional stability?

Cast your anonymous vote to register reader and diplomatic sentiment on this story.

Source ledger

This brief is based on reporting by Euronews.

supports: Euronews ↗